Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Humans | 26 | 2022 | 6794 | 1.040 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2016 | 49 | 0.910 |
Why?
|
| Bacteriuria | 1 | 2022 | 2 | 0.750 |
Why?
|
| Urinary Tract Infections | 1 | 2022 | 9 | 0.740 |
Why?
|
| Early Detection of Cancer | 2 | 2012 | 59 | 0.670 |
Why?
|
| Osteoarthritis, Knee | 2 | 2010 | 6 | 0.610 |
Why?
|
| Practice Guidelines as Topic | 3 | 2014 | 84 | 0.580 |
Why?
|
| Anticoagulants | 2 | 2009 | 14 | 0.580 |
Why?
|
| Angina, Unstable | 2 | 2009 | 5 | 0.560 |
Why?
|
| Male | 11 | 2016 | 3671 | 0.530 |
Why?
|
| Myocardial Infarction | 2 | 2009 | 46 | 0.520 |
Why?
|
| Eczema | 1 | 2016 | 1 | 0.510 |
Why?
|
| Tacrolimus | 1 | 2016 | 6 | 0.500 |
Why?
|
| Dermatologic Agents | 1 | 2016 | 2 | 0.500 |
Why?
|
| Isotretinoin | 1 | 2016 | 4 | 0.500 |
Why?
|
| Acne Vulgaris | 1 | 2016 | 4 | 0.500 |
Why?
|
| Anticonvulsants | 1 | 2016 | 9 | 0.490 |
Why?
|
| Epilepsy | 1 | 2016 | 14 | 0.490 |
Why?
|
| Female | 8 | 2022 | 4060 | 0.470 |
Why?
|
| Gout | 1 | 2015 | 1 | 0.460 |
Why?
|
| Gout Suppressants | 1 | 2015 | 2 | 0.460 |
Why?
|
| Colchicine | 1 | 2015 | 4 | 0.460 |
Why?
|
| Ureteral Calculi | 1 | 2015 | 1 | 0.450 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2015 | 3 | 0.450 |
Why?
|
| Incidental Findings | 1 | 2014 | 2 | 0.440 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 8 | 0.440 |
Why?
|
| Sinusitis | 1 | 2014 | 4 | 0.440 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 57 | 0.440 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 64 | 0.430 |
Why?
|
| Aged | 6 | 2022 | 1539 | 0.430 |
Why?
|
| Abortifacient Agents, Nonsteroidal | 1 | 2014 | 1 | 0.420 |
Why?
|
| Abortion, Incomplete | 1 | 2014 | 1 | 0.420 |
Why?
|
| Misoprostol | 1 | 2014 | 1 | 0.420 |
Why?
|
| Pregnancy Trimester, First | 1 | 2014 | 18 | 0.410 |
Why?
|
| Shoulder Pain | 1 | 2013 | 1 | 0.410 |
Why?
|
| Anatomic Landmarks | 1 | 2013 | 4 | 0.410 |
Why?
|
| Ultrasonography, Interventional | 1 | 2013 | 17 | 0.400 |
Why?
|
| Glucocorticoids | 1 | 2013 | 65 | 0.400 |
Why?
|
| Inappropriate Prescribing | 1 | 2013 | 9 | 0.390 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 19 | 0.390 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 19 | 0.390 |
Why?
|
| Polypharmacy | 1 | 2013 | 17 | 0.390 |
Why?
|
| Labor Pain | 1 | 2012 | 1 | 0.380 |
Why?
|
| Analgesia, Obstetrical | 1 | 2012 | 3 | 0.380 |
Why?
|
| Analgesia, Epidural | 1 | 2012 | 5 | 0.380 |
Why?
|
| Weight Loss | 1 | 2012 | 35 | 0.370 |
Why?
|
| Fatty Liver | 1 | 2012 | 59 | 0.360 |
Why?
|
| Middle Aged | 7 | 2011 | 2108 | 0.360 |
Why?
|
| Electrocardiography | 2 | 2009 | 36 | 0.350 |
Why?
|
| Diarrhea | 1 | 2011 | 10 | 0.350 |
Why?
|
| Probiotics | 1 | 2011 | 10 | 0.350 |
Why?
|
| Unnecessary Procedures | 1 | 2011 | 1 | 0.350 |
Why?
|
| Early Medical Intervention | 1 | 2011 | 4 | 0.340 |
Why?
|
| Prostate-Specific Antigen | 1 | 2011 | 10 | 0.340 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2012 | 92 | 0.340 |
Why?
|
| Mass Screening | 1 | 2012 | 116 | 0.330 |
Why?
|
| Homes for the Aged | 1 | 2010 | 1 | 0.330 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2010 | 2 | 0.330 |
Why?
|
| Nursing Homes | 1 | 2010 | 8 | 0.330 |
Why?
|
| Treatment Outcome | 5 | 2014 | 500 | 0.330 |
Why?
|
| Pregnancy | 3 | 2022 | 599 | 0.330 |
Why?
|
| Influenza Vaccines | 1 | 2010 | 11 | 0.330 |
Why?
|
| Influenza, Human | 1 | 2010 | 18 | 0.330 |
Why?
|
| Osteoarthritis, Hip | 1 | 2010 | 5 | 0.320 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 45 | 0.320 |
Why?
|
| Arthralgia | 1 | 2010 | 3 | 0.320 |
Why?
|
| Hypercholesterolemia | 1 | 2010 | 13 | 0.310 |
Why?
|
| Analgesics, Opioid | 1 | 2010 | 58 | 0.310 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 24 | 0.310 |
Why?
|
| Dopamine Agonists | 1 | 2009 | 3 | 0.310 |
Why?
|
| Parkinson Disease | 1 | 2009 | 6 | 0.310 |
Why?
|
| Heparin | 1 | 2009 | 8 | 0.300 |
Why?
|
| Evidence-Based Medicine | 4 | 2010 | 28 | 0.300 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2014 | 293 | 0.290 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2011 | 82 | 0.290 |
Why?
|
| Arthroscopy | 1 | 2008 | 1 | 0.290 |
Why?
|
| Debridement | 1 | 2008 | 5 | 0.290 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2008 | 17 | 0.280 |
Why?
|
| Atrial Fibrillation | 1 | 2008 | 16 | 0.280 |
Why?
|
| Occupational Therapy | 1 | 2007 | 2 | 0.260 |
Why?
|
| Stroke Rehabilitation | 1 | 2007 | 3 | 0.260 |
Why?
|
| Activities of Daily Living | 1 | 2007 | 19 | 0.260 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2006 | 2 | 0.250 |
Why?
|
| Alzheimer Disease | 1 | 2006 | 30 | 0.240 |
Why?
|
| Administration, Oral | 3 | 2010 | 54 | 0.230 |
Why?
|
| Administration, Cutaneous | 2 | 2016 | 6 | 0.210 |
Why?
|
| Family Practice | 2 | 2016 | 21 | 0.190 |
Why?
|
| Hematuria | 1 | 2022 | 4 | 0.190 |
Why?
|
| Urinalysis | 1 | 2022 | 5 | 0.190 |
Why?
|
| Nitrites | 1 | 2022 | 8 | 0.190 |
Why?
|
| Sensitivity and Specificity | 1 | 2022 | 98 | 0.180 |
Why?
|
| Infant | 1 | 2022 | 187 | 0.180 |
Why?
|
| Risk Assessment | 2 | 2013 | 197 | 0.170 |
Why?
|
| Survival Analysis | 2 | 2011 | 95 | 0.160 |
Why?
|
| Administration, Topical | 1 | 2016 | 20 | 0.130 |
Why?
|
| Dermatitis, Atopic | 1 | 2016 | 5 | 0.130 |
Why?
|
| Remission Induction | 1 | 2016 | 5 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 31 | 0.120 |
Why?
|
| Time Factors | 1 | 2016 | 321 | 0.110 |
Why?
|
| Ovarian Diseases | 1 | 2014 | 1 | 0.110 |
Why?
|
| Adrenal Gland Diseases | 1 | 2014 | 3 | 0.110 |
Why?
|
| Pituitary Diseases | 1 | 2014 | 2 | 0.110 |
Why?
|
| Education, Medical, Continuing | 1 | 2014 | 11 | 0.110 |
Why?
|
| Adrenal Glands | 1 | 2014 | 11 | 0.110 |
Why?
|
| Ovary | 1 | 2014 | 19 | 0.110 |
Why?
|
| Pancreatic Diseases | 1 | 2014 | 11 | 0.110 |
Why?
|
| Lung Diseases | 1 | 2014 | 9 | 0.110 |
Why?
|
| Pituitary Gland | 1 | 2014 | 40 | 0.110 |
Why?
|
| Thyroid Diseases | 1 | 2014 | 25 | 0.110 |
Why?
|
| Liver Diseases | 1 | 2014 | 19 | 0.110 |
Why?
|
| Thyroid Gland | 1 | 2014 | 28 | 0.110 |
Why?
|
| Vacuum Curettage | 1 | 2014 | 1 | 0.110 |
Why?
|
| Pancreas | 1 | 2014 | 144 | 0.100 |
Why?
|
| Liver | 1 | 2014 | 157 | 0.100 |
Why?
|
| Lung | 1 | 2014 | 106 | 0.100 |
Why?
|
| Kidney | 1 | 2014 | 184 | 0.100 |
Why?
|
| United States | 1 | 2016 | 1019 | 0.090 |
Why?
|
| Correspondence as Topic | 1 | 2012 | 1 | 0.090 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2012 | 35 | 0.090 |
Why?
|
| Risk Factors | 1 | 2014 | 767 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2012 | 145 | 0.090 |
Why?
|
| Meta-Analysis as Topic | 1 | 2011 | 5 | 0.090 |
Why?
|
| Asymptomatic Diseases | 1 | 2011 | 5 | 0.090 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 497 | 0.090 |
Why?
|
| Evidence-Based Practice | 1 | 2011 | 8 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 112 | 0.080 |
Why?
|
| Child, Preschool | 1 | 2011 | 258 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 268 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2011 | 167 | 0.080 |
Why?
|
| Young Adult | 1 | 2012 | 567 | 0.080 |
Why?
|
| Pain Measurement | 1 | 2010 | 51 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 155 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 1 | 2010 | 115 | 0.070 |
Why?
|
| Palliative Care | 1 | 2008 | 22 | 0.070 |
Why?
|
| Coronary Angiography | 1 | 2007 | 71 | 0.060 |
Why?
|